CNS Pharmaceuticals to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech
CNS Pharmaceuticals (NASDAQ:CNSP), a biopharmaceutical company focused on developing treatments for brain and central nervous system cancers, will participate in the upcoming Webull Financial Corporate Connect Webinar Series: Biotech/MedTech. The virtual presentation will be delivered by CEO John Climaco on Tuesday, August 19, 2025, at 2:40 PM ET.
CNS Pharmaceuticals (NASDAQ:CNSP), una societ脿 biofarmaceutica specializzata nello sviluppo di terapie per i tumori cerebrali e del sistema nervoso centrale, parteciper脿 alla serie di webinar Webull Financial Corporate Connect: Biotech/MedTech. La presentazione virtuale sar脿 tenuta dal CEO John Climaco marted矛 19 agosto 2025 alle 14:40 ET.
CNS Pharmaceuticals (NASDAQ:CNSP), una compa帽铆a biofarmac茅utica dedicada al desarrollo de tratamientos para c谩nceres cerebrales y del sistema nervioso central, participar谩 en la serie de seminarios web Webull Financial Corporate Connect: Biotech/MedTech. La presentaci贸n virtual correr谩 a cargo del CEO John Climaco el martes 19 de agosto de 2025 a las 2:40 PM ET.
CNS Pharmaceuticals (NASDAQ:CNSP)電� 雵� 氚� 欷戩稊鞁犼步瓿� 鞎� 旃橂鞝� 臧滊皽鞐� 欤茧牓頃橂姅 氚旍澊鞓れ牅鞎届偓搿�, Webull Financial鞚� Corporate Connect 鞗箘雮� 鞁滊Μ歃�: Biotech/MedTech鞐� 彀戈皜頃╇媹雼�. 鞓澕鞚� 氚滍憸電� CEO John Climaco臧� 2025雲� 8鞗� 19鞚� 頇旍殧鞚� 霃欕秬鞁滉皠(ET) 鞓ろ泟 2鞁� 40攵勳棎 歆勴枆頃╇媹雼�.
CNS Pharmaceuticals (NASDAQ:CNSP), une soci茅t茅 biopharmaceutique sp茅cialis茅e dans le d茅veloppement de traitements pour les cancers du cerveau et du syst猫me nerveux central, participera 脿 la s茅rie de webinaires Webull Financial Corporate Connect : Biotech/MedTech. La pr茅sentation virtuelle sera assur茅e par le CEO John Climaco le mardi 19 ao没t 2025 脿 14h40 (heure de l'Est, ET).
CNS Pharmaceuticals (NASDAQ:CNSP), ein Biopharmaunternehmen, das sich auf die Entwicklung von Therapien f眉r Hirn- und Erkrankungen des zentralen Nervensystems spezialisiert hat, wird an der Webinar-Reihe Webull Financial Corporate Connect: Biotech/MedTech teilnehmen. Die virtuelle Pr盲sentation h盲lt CEO John Climaco am Dienstag, den 19. August 2025 um 14:40 Uhr ET.
- None.
- None.
- Live video webcast on Tuesday, August 19th at 2:40 PM ET
HOUSTON, TX / / August 14, 2025 / ) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that it will present at the being held virtually August 19-21, 2025
Details for the presentation are as follows:
Date and Time: Tuesday, August 19, 2025 at 2:40 PM ET
Presenter:
Registration Link:
About Webull Financial
Webull Financial is a leading online brokerage platform committed to empowering self-directed investors with innovative tools and cutting-edge technology. With low-cost trading on a wide range of assets, advanced charting tools, and real-time market data, Webull is revolutionizing the way individuals approach investing. The user-centric approach and commitment to staying at the forefront of industry trends underscore the mission to provide a seamless and rewarding experience for traders of all levels. Through the Webull Group, Webull Financial and its affiliates combine to serve tens of millions of users from over 180 countries worldwide. Securities and futures trading is offered to customers by Webull Financial LLC ("Webull Financial"), a broker-dealer registered with the Securities and Exchange Commission (SEC) and a futures commission merchant registered with the Commodity Futures Trading Commission (CFTC). Webull Financial is a member of the Financial Industry Authority (FINRA), the National Futures Association (NFA), and the Securities Investor Protection Corporation (SIPC). All investing is subject to risk, including the possible loss of principal. For more information about Webull, visit .
About CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system.
The Company's drug candidate TPI 287 is an abeotaxane, which stabilizes microtubules and inhibits cell division, causing apoptosis and cell death. The initial clinical efficacy data suggest TPI 287 has the potential to cross the blood-brain barrier and treat CNS tumors. TPI 287 also has been tested in over 350 patients in clinical trials as a monotherapy and in combination with bevacizumab for the treatment of a range of diseases or conditions, including recurrent glioblastoma, recurrent neuroblastoma and medulloblastoma, advanced malignancies, progressive neoplastic disease, advanced unresectable pancreatic cancer, metastatic melanoma, and breast cancer metastatic to the brain. To date TPI 287 appears to have both an excellent safety profile and high tolerability among patients.
For more information, please visit , and connect with the Company on , , and.
CONTACTS:
Investor Relations Contact
JTC Team, LLC
Jenene Thomas
908.824.0775
[email protected]
SOURCE: CNS Pharmaceuticals, Inc.
View the original on ACCESS Newswire
FAQ
When is CNS Pharmaceuticals (CNSP) presenting at the Webull Financial Webinar Series?
Who will be presenting for CNS Pharmaceuticals at the Webull Financial Webinar?
What type of company is CNS Pharmaceuticals (CNSP)?
What is the format of the Webull Financial Corporate Connect Webinar Series?
